Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
在納斯達克全球市場（納斯達克股票代碼：MNOV）和東京證券交易所標準市場（代碼編號：4875）上市的生物製藥公司MedicinOVA, Inc. 宣佈已收到美國專利商標局對一項待處理的專利申請的批准通知，該專利申請涵蓋了新冠肺炎後條件下的 MN-166（ibudilast）。該使用方法專利涵蓋使用具有治療效果的伊布地拉特（或藥學上可接受的鹽）以緩解一系列後COVID疾病，包括焦慮、疲勞、抑鬱、呼吸急促、創傷後應激障礙、胸悶、心悸、嗅覺或味覺功能障礙、睡眠困難、脫髮和皮疹。
